Diagnosis of type 3 macular neovascularization Review article
Article Sidebar
Published:
Sep 30, 2021
Keywords:
wet age-related macular degeneration, macular neovascularization, optical coherence tomography angiography, anti-VEGF therapy
Main Article Content
Abstract
Type 3 macular neovascularization is characterized by a complex of pathological vessels located in the sensory retina. Fundus oculi examination reveals intraretinal hemorrhages, macular edema, hard exudates and pigment epithelial detachments. Indocyanine and fluorescein angiography, OCT and angio-OCT are used for diagnosis and treatment monitoring. The treatment efficacy depends on the disease severity and the therapy applied.
Downloads
Download data is not yet available.
Article Details
How to Cite
1.
Mędrzycka J, Piotrowicz A, Gołębiewska J, Różycki R. Diagnosis of type 3 macular neovascularization. Ophthatherapy [Internet]. 2021Sep.30 [cited 2024Nov.16];8(3):153-8. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/1512
Issue
Section
Diagnostics
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Yannuzzi LA, Freund KB, Takahashi BS. Review of retinal angiomatous proliferation or type 3 neovascularization. Retina. 2008; 28(3): 375-84.
2. Hartnett ME, Weiter JJ, Garsd A et al. Classification of retinal pigment epithelial detachments associated with drusen. Graefes Arch Clin Exp Ophthalmol. 1992; 230(1): 11-9. http://doi.org/10.1007/BF00166756.
3. Tsai ASH, Cheung N, Gan ATL et al. Retinal angiomatous proliferation. Surv Ophthalmol. 2017; 62(4): 462-92. http://doi.org/10.1016/j.survophthal.2017.01.
4. Gołębiewska J, Hautz W. Zastosowanie angio-OCT w diagnostyce i terapii okulistycznej – część I. OphthaTherapy. 2016; 3(3): 161-71.
5. Campa C, Harding S, Pearce I et al. Incidence of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Eye. 2010; 24: 1585-9. http://doi.org/10.1038/eye.2010.88.
6. Kałużny JJ, Zabel K, Zabel P. Proliferacje naczyniakowate siatkówki – epidemiologia, obraz kliniczny i leczenie. Okulistyka. 2021: 21-6.
7. Bearelly S, Espinosa-Heidmann DG, Cousins SW. The role of dynamic indocyanine green angiography in the diagnosis and treatment of retinal angiomatous proliferation. Br J Ophthalmol. 2008; 92(2): 191-6.
8. Öztaş Z, Menteş J. Retinal Angiomatous Proliferation: Multimodal Imaging Characteristics and Follow-up with Eye-Tracked Spectral Domain Optical Coherence Tomography of Precursor Lesions. Turk J Ophthalmol. 2018; 48(2): 66-9.
9. Rispoli M, Cennamo G, Di Antonio L et al. Imaging Biomarkers in Exudative AMD. Biomedicines. 2021; 9(6): 668.
10. Querques G, Miere A, Souied EH. Optical Coherence Tomography Angiography Features of Type 3 Neovascularization in Age-Related Macular Degeneration. Dev Ophthalmol. 2016; 56: 57-61. http://doi.org/10.1159/000442779. Epub 2016.
11. Boscia F, Parodi MB, Furino C et al. Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2006; 244(10): 1224-32. http://doi.org/10.1007/s00417-005-0205-2. Epub 2006.
12. Stoffelns BM, Kramann C, Schoepfer K. Laserfotokoagulation und photodynamische Therapie (PDT) zur Behandlung der retinalen angiomatösen Proliferation (RAP) bei feuchter altersabhängiger Makuladegeneration (AMD) [Laser photocoagulation and photodynamic therapy (PDT) with verteporfin for retinal angiomatous proliferation (RAP) in age-related macular degeneration (AMD)]. Klin Monbl Augenheilkd. 2008; 225(5): 392-6. http://doi.org/10.1055/s-2008-1027251.
13. Rouvas AA, Papakostas TD, Vavvas D et al. Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. Retina. 2009; 29(4): 536-44. http://doi.org/10.1097/IAE.0b013e318196b1de.
14. Krebs I, Krepler K, Stolba U et al. Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone. Graefes Arch Clin Exp Ophthalmol. 2008; 246(2): 237-43. http://doi.org/10.1007/s00417-007-0651-0 . Epub 2007.
15. Nakano S, Honda S, Oh H et al. Effect of photodynamic therapy (PDT), posterior subtenon injection of triamcinolone acetonide with PDT, and intravitreal injection of ranibizumab with PDT for retinal angiomatous proliferation. Clin Ophthalmol. 2012; 6: 277-82. http://doi.org/10.2147/OPTH.S29718. Epub 2012.
16. Saito M, Iida T, Kano M. Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol. 2012; 153(3): 504-14.e1. http://doi.org/10.1016/j.ajo.2011.08.038. Epub 2011.
17. Malamos P, Tservakis I, Kanakis M et al. Long-Term Results of Combination Treatment with Single-Dose Ranibizumab plus Photodynamic Therapy for Retinal Angiomatous Proliferation. Ophthalmologica. 2018; 240(4): 213-21. http://doi.org/10.1159/000487610. Epub 2018.
18. Mantel I, Ambresin A, Zografos L. Retinal angiomatous proliferation treated with a combination of intravitreal triamcinolone acetonide and photodynamic therapy with verteporfin. Eur J Ophthalmol. 2006; 16(5): 705-10. http://doi.org/10.1177/112067210601600507.
19. Hata M, Yamashiro K, Oishi A et al. Retinal pigment epithelial atrophy after anti-vascular endothelial growth factor injections for retinal angiomatous proliferation. Retina. 2017; 37(11): 2069-77. http://doi.org/10.1097/IAE.0000000000001457.
2. Hartnett ME, Weiter JJ, Garsd A et al. Classification of retinal pigment epithelial detachments associated with drusen. Graefes Arch Clin Exp Ophthalmol. 1992; 230(1): 11-9. http://doi.org/10.1007/BF00166756.
3. Tsai ASH, Cheung N, Gan ATL et al. Retinal angiomatous proliferation. Surv Ophthalmol. 2017; 62(4): 462-92. http://doi.org/10.1016/j.survophthal.2017.01.
4. Gołębiewska J, Hautz W. Zastosowanie angio-OCT w diagnostyce i terapii okulistycznej – część I. OphthaTherapy. 2016; 3(3): 161-71.
5. Campa C, Harding S, Pearce I et al. Incidence of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Eye. 2010; 24: 1585-9. http://doi.org/10.1038/eye.2010.88.
6. Kałużny JJ, Zabel K, Zabel P. Proliferacje naczyniakowate siatkówki – epidemiologia, obraz kliniczny i leczenie. Okulistyka. 2021: 21-6.
7. Bearelly S, Espinosa-Heidmann DG, Cousins SW. The role of dynamic indocyanine green angiography in the diagnosis and treatment of retinal angiomatous proliferation. Br J Ophthalmol. 2008; 92(2): 191-6.
8. Öztaş Z, Menteş J. Retinal Angiomatous Proliferation: Multimodal Imaging Characteristics and Follow-up with Eye-Tracked Spectral Domain Optical Coherence Tomography of Precursor Lesions. Turk J Ophthalmol. 2018; 48(2): 66-9.
9. Rispoli M, Cennamo G, Di Antonio L et al. Imaging Biomarkers in Exudative AMD. Biomedicines. 2021; 9(6): 668.
10. Querques G, Miere A, Souied EH. Optical Coherence Tomography Angiography Features of Type 3 Neovascularization in Age-Related Macular Degeneration. Dev Ophthalmol. 2016; 56: 57-61. http://doi.org/10.1159/000442779. Epub 2016.
11. Boscia F, Parodi MB, Furino C et al. Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2006; 244(10): 1224-32. http://doi.org/10.1007/s00417-005-0205-2. Epub 2006.
12. Stoffelns BM, Kramann C, Schoepfer K. Laserfotokoagulation und photodynamische Therapie (PDT) zur Behandlung der retinalen angiomatösen Proliferation (RAP) bei feuchter altersabhängiger Makuladegeneration (AMD) [Laser photocoagulation and photodynamic therapy (PDT) with verteporfin for retinal angiomatous proliferation (RAP) in age-related macular degeneration (AMD)]. Klin Monbl Augenheilkd. 2008; 225(5): 392-6. http://doi.org/10.1055/s-2008-1027251.
13. Rouvas AA, Papakostas TD, Vavvas D et al. Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. Retina. 2009; 29(4): 536-44. http://doi.org/10.1097/IAE.0b013e318196b1de.
14. Krebs I, Krepler K, Stolba U et al. Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone. Graefes Arch Clin Exp Ophthalmol. 2008; 246(2): 237-43. http://doi.org/10.1007/s00417-007-0651-0 . Epub 2007.
15. Nakano S, Honda S, Oh H et al. Effect of photodynamic therapy (PDT), posterior subtenon injection of triamcinolone acetonide with PDT, and intravitreal injection of ranibizumab with PDT for retinal angiomatous proliferation. Clin Ophthalmol. 2012; 6: 277-82. http://doi.org/10.2147/OPTH.S29718. Epub 2012.
16. Saito M, Iida T, Kano M. Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol. 2012; 153(3): 504-14.e1. http://doi.org/10.1016/j.ajo.2011.08.038. Epub 2011.
17. Malamos P, Tservakis I, Kanakis M et al. Long-Term Results of Combination Treatment with Single-Dose Ranibizumab plus Photodynamic Therapy for Retinal Angiomatous Proliferation. Ophthalmologica. 2018; 240(4): 213-21. http://doi.org/10.1159/000487610. Epub 2018.
18. Mantel I, Ambresin A, Zografos L. Retinal angiomatous proliferation treated with a combination of intravitreal triamcinolone acetonide and photodynamic therapy with verteporfin. Eur J Ophthalmol. 2006; 16(5): 705-10. http://doi.org/10.1177/112067210601600507.
19. Hata M, Yamashiro K, Oishi A et al. Retinal pigment epithelial atrophy after anti-vascular endothelial growth factor injections for retinal angiomatous proliferation. Retina. 2017; 37(11): 2069-77. http://doi.org/10.1097/IAE.0000000000001457.